Medical Faculty

Ljubljana, Slovenia

Medical Faculty

Ljubljana, Slovenia
SEARCH FILTERS
Time filter
Source Type

News Article | May 3, 2017
Site: www.eurekalert.org

Phthalates, which are used as plasticizers in plastics, can considerably increase the risk of allergies among children. This was demonstrated by UFZ researchers in conjunction with scientists from the University of Leipzig and the German Cancer Research Center (DKFZ) in a current study published in the Journal of Allergy and Clinical Immunology. According to this study, an increased risk of children developing allergic asthma exists if the mother has been particularly heavily exposed to phthalates during pregnancy and breastfeeding. The mother-child cohort from the LINA study was the starting and end point of this translational study. In our day-to-day lives, we come into contact with countless plastics containing plasticizers. These plasticizers, which also include the aforementioned phthalates, are used when processing plastics in order to make the products more flexible. Phthalates can enter our bodies through the skin, foodstuffs or respiration. "It is a well-known fact that phthalates affect our hormone system and can thereby have an adverse effect on our metabolism or fertility. But that's not the end of it," says UFZ environmental immunologist Dr Tobias Polte. "The results of our current study demonstrate that phthalates also interfere with the immune system and can significantly increase the risk of developing allergies." At the outset of the study, the team of UFZ researchers examined the urine of pregnant women from the LINA (lifestyle and environmental factors and their influence on the newborn-allergy-risk) mother-child cohort study and searched for metabolites of phthalates. The concentration level determined in each case was found to correlate with the occurrence of allergic asthma among the children. "There was a clearly discernible relationship between higher concentrations of the metabolite of benzylbutylphthalate (BBP) in the mother's urine and the presence of allergic asthma in their children", explains Dr Irina Lehmann, who heads the LINA study. Researchers were able to confirm the results from the mother-child cohort in the mouse model in collaboration with colleagues from the Medical Faculty at the University of Leipzig. In this process, mice were exposed to a certain phthalate concentration during pregnancy and the lactation period, which led to comparable concentrations of the BBP metabolite in urine to those observed in heavily exposed mothers from the LINA cohort. The offspring demonstrated a clear tendency to develop allergic asthma; even the third generation continued to be affected. Among the adult mice, on the other hand, there were no increased allergic symptoms. "The time factor is therefore decisive: if the organism is exposed to phthalates during the early stages of development, this may have effects on the risk of illness for the two subsequent generations," explains Polte. "The prenatal development process is thus clearly altered by the phthalate exposure." In order to establish precisely what may have been modified, Polte and his team, in collaboration with colleagues from the German Cancer Research Center (DKFZ), took a close look at the genes of the young mice born to exposed mothers. So-called methyl groups were found in the DNA of these genes - and to a greater extent than is usually the case. In the course of this so-called epigenetic modification of the DNA, methyl groups attach themselves to a gene like a kind of padlock and thus prevent its code from being read, meaning that the associated protein cannot be produced. After the researchers treated the mice with a special substance intended to crack the methyl "locks" on the affected genes, the mice demonstrated fewer signs of allergic asthma than before. Dr Polte concludes the following: "Phthalates apparently switch off decisive genes by means of DNA methylation, causing the activity of these genes to be reduced in the young mice." But which genes cause allergic asthma if they cannot be read? So-called T-helper 2 cells play a central part in the development of allergies. These are kept in check by special opponents (repressors). If a repressor gene cannot be read as a result of being blocked by methyl groups, the T-helper 2 cells that are conducive to the development of allergies are no longer sufficiently inhibited, meaning that an allergy is likely to develop. "We surmise that this connection is decisive for the development of allergic asthma caused by phthalates," says Polte. "Furthermore, in the cell experiment, we were able to demonstrate that there is an increased formation of T-helper 2 cells from the immune cells of the offspring of exposed mother mice than is the case for the offspring of non-exposed animals. This enabled us to establish an increased tendency towards allergies once again." In mice, the researchers were able to prove that a repressor gene that has been switched off due to DNA methylation is responsible for the development of allergic asthma. But does this mechanism also play a part in humans? In order to answer this question, the researchers consulted the LINA cohort once more. They searched for the corresponding gene among the children with allergic asthma and studied the degree of methylation and gene activity. Here, too, it became apparent that the gene was blocked by methyl groups and thus could not be read. "Thanks to our translational study approach - which led from humans via the mouse model and cellular culture back to humans again - we have been able to demonstrate that epigenetic modifications are apparently responsible for the fact that children of mothers who had a high exposure to phthalates during pregnancy and breastfeeding have an increased risk of developing allergic asthma," says Polte. "The objective of our further research will be to understand exactly how specific phthalates give rise to the methylation of genes which are relevant for the development of allergies." Susanne Jahreis, Saskia Trump, Mario Bauer, Tobias Bauer, Loreen Thu?rmann, Ralph Feltens, Qi Wang, Lei Gu, Konrad Gru?tzmann, Stefan Röder, Marco Averbeck, Dieter Weichenhan, Christoph Plass, Ulrich Sack, Michael Borte, Virginie Dubourg, Gerrit, Schu?u?rmann, Jan C. Simon, Martin von Bergen, Jörg Hackermu?ller, Roland Eils, Irina Lehmann, Tobias Polte (2017): Maternal phthalate exposure promotes allergic airway inflammation over two generations via epigenetic modifications, Journal of Allergy and Clinical Immunology; doi: 10.1016/j.jaci.2017.03.017; http://doi. PD Dr Tobias Polte Head of the Helmholtz University Research Group "Experimental Allergology and Immunology" Tel.: +49 341 235-1545 E-mail: tobias.polte@ufz.de https:/ Dr Irina Lehmann Head of the UFZ Department of Environmental Immunology Tel.: +49 341 235-1216 Email: irina.lehmann@ufz.de http://www.


NOXXON Pharma N.V. (Paris:ALNOX) (Alternext Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, today announced the signing of an agreement with the National Center for Tumor Diseases (NCT) in Heidelberg under which the NCT will conduct a trial evaluating NOXXON’s lead product candidate NOX-A12 in combination with Keytruda® (pembrolizumab) in metastatic pancreatic and colorectal cancer. In some preclinical studies, NOX-A12 has shown an ability to make the immediate area surrounding a model tumor, the so-called tumor microenvironment, more accessible to the immune system. The ability of many tumors to use the tumor microenvironment to hide from the immune system is believed to contribute to the insensitivity of some tumors towards checkpoint inhibitors, such as Keytruda®. The NCT is a leading center for cancer research and treatment, located in Heidelberg, Germany. It was jointly founded by the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Medical Faculty Heidelberg and German Cancer Aid (Deutsche Krebshilfe) in 2004 to conduct interdisciplinary research for preventing and treating cancer to ultimately benefit patients. The NCT investigators leading the clinical trial include Prof. Dr. Dirk Jäger, Managing Director, head of the clinical and tumor immunology research groups, and Dr. Niels Halama, Group Leader, both recognized leaders in clinical cancer research with significant experience in studying the tumor microenvironment in a clinical setting. Throughout his career, Prof. Dr. Jäger has focused on tumor and immunology as well as the interdisciplinary connections between both fields, both scientifically and clinically. NOXXON’s Chief Medical Officer, Dr. Jarl Ulf Jungnelius, commented: “Dr. Jäger and Dr. Halama are experts in the treatment of metastatic cancer patients as well as the tumor microenvironment. We are extremely pleased that they will be collaborating with NOXXON on this groundbreaking study.” Prof. Dr. Jäger, Managing Director of the NCT Heidelberg, commented: “This trial will enable us to explore the potential of NOX-A12 in combination with Keytruda® to benefit patients with few viable treatment options. Importantly, the trial will help us to better understand the ability of NOX-A12 to modify the tumor microenvironment and make it more accessible to the immune system to facilitate tumor destruction.” NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON’s Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Keytruda® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com About the National Center for Tumor Diseases (NCT) Heidelberg The NCT Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden. Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


Aarse J.,Medical Faculty | Herlitze S.,Ruhr University Bochum | Manahan-Vaughan D.,Medical Faculty
Hippocampus | Year: 2016

Brain-derived neurotrophic factor (BDNF) supports neuronal survival, growth, and differentiation and has been implicated in forms of hippocampus-dependent learning. In vitro, a specific role in hippocampal synaptic plasticity has been described, although not all experience-dependent forms of synaptic plasticity critically depend on BDNF. Synaptic plasticity is likely to enable long-term synaptic information storage and memory, and the induction of persistent (>24 h) forms, such as long-term potentiation (LTP) and long-term depression (LTD) is tightly associated with learning specific aspects of a spatial representation. Whether BDNF is required for persistent (>24 h) forms of LTP and LTD, and how it contributes to synaptic plasticity in the freely behaving rodent has never been explored. We examined LTP, LTD, and related forms of learning in the CA1 region of freely dependent mice that have a partial knockdown of BDNF (BDNF+/-). We show that whereas early-LTD (<90min) requires BDNF, short-term depression (<45 min) does not. Furthermore, BDNF is required for LTP that is induced by mild, but not strong short afferent stimulation protocols. Object-place learning triggers LTD in the CA1 region of mice. We observed that object-place memory was impaired and the object-place exploration failed to induce LTD in BDNF+/- mice. Furthermore, spatial reference memory, that is believed to be enabled by LTP, was also impaired. Taken together, these data indicate that BDNF is required for specific, but not all, forms of hippocampal-dependent information storage and memory. Thus, very robust forms of synaptic plasticity may circumvent the need for BDNF, rather it may play a specific role in the optimization of weaker forms of plasticity. The finding that both learning-facilitated LTD and spatial reference memory are both impaired in BDNF+/- mice, suggests moreover, that it is critically required for the physiological encoding of hippocampus-dependent memory. © 2015 The Authors Hippocampus Published by Wiley Periodicals, Inc.


News Article | November 19, 2016
Site: www.sciencedaily.com

Infectious diseases are a leading cause of mortality worldwide. The development of novel therapies or vaccines requires improved understanding of how viruses, pathogenic fungi or bacteria cause illnesses. Some bacterial pathogens such as Salmonella invade and replicate within human cells. Science is steadily shifting its focus towards studying infected cells and how differences between individual host cells affect the cellular response to pathogens. A research team headed by Professor Jörg Vogel from the University of Würzburg has made significant progress in this area. They have developed a novel technique that allows them to investigate the interplay of individual host cells with infecting bacteria. This study is based on close collaboration between Jörg Vogel's team at the Institute of Molecular Infection Biology, the core unit Systems Medicine of the Medical Faculty and researchers at Imperial College in London. Their results have now been published in the scientific journal Nature Microbiology. The team used a technique called "single-cell RNA-seq" to study the infection of macrophages by Salmonella. Macrophages are immune cells that belong to the group of white blood cells. Salmonella on the other hand are pathogenic bacteria that may be taken up by the ingestion of contaminated water or food to cause local gastroenteritis and diarrhea. In immunocompromised patients however, Salmonella may disseminate throughout the entire body and cause life-threatening diseases. Upon the invasion of macrophages, Salmonella pursue two strategies: The bacteria either replicate to high numbers inside the host cell or adopt a non-growing state that allows them to persist for years within the body of their host. "This disparate growth behavior impacts disease progression and plays a major role in the success of antibiotic treatment" says lead researcher Jörg Vogel. To date, very little is known if and how macrophages respond to these disparate lifestyles of intracellular Salmonella. To answer this question the Würzburg scientists cultured macrophages in the laboratory and infected them with Salmonella. The RNA from the infected cells was subsequently extracted and analyzed using deep-sequencing, leading to the detection of more than 5,000 different transcripts per macrophage. These data on the host's gene expression were combined with information about the growth behavior of the intracellular pathogens. The results: Macrophages containing non-growing bacteria adopt the hallmark signature associated with inflammation. They express signaling molecules to attract further immune cells to the site of infection. In this respect, they respond similarly to macrophages that have encountered Salmonella, but have not been infected. "These macrophages cannot detect their intracellular bacteria -- they are below their radar" explains Emmanuel Saliba, first author of the study. In contrast, macrophages with fast-growing bacteria develop an anti-inflammatory response. These interesting results open many questions, Do Salmonella induce this different response? Do they manipulate the macrophages so they do not raise the alarm to facilitate the bacteria to evade an immune response? Are there situations where Salmonella are unable to perform this trick? In these cases, will there still be an immune response forcing the bacteria to switch to their resting growth state? Of interest for many biomedical areas "Currently we have just looked at a single time point after infection and thus cannot differentiate between cause and consequence" explains Alexander Westermann, another member of the team. Follow-up studies are required. Nevertheless, the current findings already provide a new perspective on the host response to pathogenic microbes. And using the new technology, bacterial infections can be studied in unprecedented resolution -- namely on the single-cell level. The method established at the Würzburg core unit Systems Medicine should be of great interest for many further biomedical projects. "Among others, heterogeneity amongst tumor cells or the effect of drugs on single cells may be analyzed in unknown accuracy" says Professor Vogel.

Loading Medical Faculty collaborators
Loading Medical Faculty collaborators